Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Coherus BioSciences Inc (NASDAQ:CHRS)

During the Trading Day
30.56 +1.04 / +3.52%
As of 1:00pm ET
Day’s Change
During After-Hours   Switch to standard view »
30.56 0.00 / 0.00%
Volume: 291.00
Health Technology

Company Description

Coherus BioSciences, Inc. is a biologics platform company with the cutting-edge analytics, process science, and clinical and regulatory capabilities to develop and commercialize biosimilar therapeutics worldwide. Its clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor, a substance in the body that is involved in the inflammatory response; and a long-acting form of granulocyte colony-stimulating factor, a beneficial substance in the body that stimulates production of granulocytes (a type of white blood cell) in order to promote the body's ability to fight infections. Coherus BioSciences was founded by Dennis M. Lanfear and Stuart E. Builder in September 2010 and is headquartered in Redwood City, CA.

Contact Information

Coherus BioSciences, Inc.
201 Redwood Shores Parkway
Redwood City California 94065
P:(650) 649-3530
Investor Relations:
(650) 649-3577



Individual stakeholders41.16%
Mutual fund holders22.74%
Other institutional20.61%

Top Executives

Denny M. LanfearChairman, President & Chief Executive Officer
Jean-Frédéric ViretChief Financial Officer
Alan C. HermanChief Scientific Officer
Peter K. WatlerChief Technical Officer
Barbara K. FinckChief Medical Officer